These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19484470)

  • 1. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
    Tsimberidou AM; Rudek MA; Hong D; Ng CS; Blair J; Goldsweig H; Kurzrock R
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):235-41. PubMed ID: 19484470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
    J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
    Furuse J; Kurata T; Okano N; Fujisaka Y; Naruge D; Shimizu T; Kitamura H; Iwasa T; Nagashima F; Nakagawa K
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):511-519. PubMed ID: 29992354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
    Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
    J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salirasib in the treatment of pancreatic cancer.
    Bustinza-Linares E; Kurzrock R; Tsimberidou AM
    Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
    Mor A; Kloog Y; Keren G; George J
    Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras chaperones: new targets for cancer and immunotherapy.
    Kloog Y; Elad-Sfadia G; Haklai R; Mor A
    Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
    Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
    Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
    Ling Y; Ye X; Ji H; Zhang Y; Lai Y; Peng S; Tian J
    Bioorg Med Chem; 2010 May; 18(10):3448-56. PubMed ID: 20435479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interactions of antineoplastic agents with other drugs].
    Drzewoski J; Robak T
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):145-8. PubMed ID: 2216954
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
    Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
    Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
    Aizman E; Mor A; Chapman J; Assaf Y; Kloog Y
    J Neuroimmunol; 2010 Dec; 229(1-2):192-203. PubMed ID: 20869125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
    Zundelevich A; Elad-Sfadia G; Haklai R; Kloog Y
    Mol Cancer Ther; 2007 Jun; 6(6):1765-73. PubMed ID: 17541036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
    Halaschek-Wiener J; Kloog Y; Wacheck V; Jansen B
    J Invest Dermatol; 2003 Jan; 120(1):109-15. PubMed ID: 12535206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of TRPA1 by farnesyl thiosalicylic acid.
    Maher M; Ao H; Banke T; Nasser N; Wu NT; Breitenbucher JG; Chaplan SR; Wickenden AD
    Mol Pharmacol; 2008 Apr; 73(4):1225-34. PubMed ID: 18171730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
    Ling Y; Wang Z; Zhu H; Wang X; Zhang W; Wang X; Chen L; Huang Z; Zhang Y
    Bioorg Med Chem; 2014 Jan; 22(1):374-80. PubMed ID: 24300920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.